All Posts By

Smartkarma Daily Briefs

Daily Brief Australia: Whispir Ltd, SiteMinder, Amaero International Ltd, Recce Ltd and more

By | Australia, Daily Briefs

In today’s briefing:

  • Whispir (WSP AU): Soprano & Pendula Jostle for Control
  • Quiddity Leaderboard ASX Mar 24: Allkem, Newmont, Costa, and Many More
  • Amaero International Ltd – Several Milestones Tracking Ahead of Schedule
  • Recce Pharmaceuticals – Landmark commitment helps fund R&D costs


Whispir (WSP AU): Soprano & Pendula Jostle for Control

By David Blennerhassett

  • On the 6 November, cloud communication outfit Whispir (WSP AU)  announced a A$0.46/share unconditional Offer, in cash, from mobile messaging software play Soprano Design.
  • The Offer price was a 92% premium to Whispir’s recent private placement, and a 60% premium to the undisturbed price. Whispir rejected the Offer.
  • Pendula subsequently emerged with a A$0.57/share NBIO. Soprano “countered” with A$0.52/share. Pendula upped its indicative Offer to A$0.60/share. An independent expert’s fair value is between A$0.486/share-A$0.565/share.

Quiddity Leaderboard ASX Mar 24: Allkem, Newmont, Costa, and Many More

By Janaghan Jeyakumar, CFA

  • In this insight, we take a look at the potential index changes for ASX 300, 200, 100, 50, and 20 in the run-up to the March 2024 index review.
  • I expect one change for ASX 20, one change for ASX 100, and four changes for ASX 200 during the March 2024 index rebal event.
  • Separately, there could also be one intra-review change for ASX 200 in February 2024.

Amaero International Ltd – Several Milestones Tracking Ahead of Schedule

By Research as a Service (RaaS)

  • Amaero International Ltd (ASX:3DA) is a global specialist in advanced materials manufacturing for the defence, aerospace, and other industrial sectors.
  • The company is developing a 1,000+-tonne-a-year critical metals alloy powder manufacturing facility in Tennessee, USA with its initial focus on producing refractory alloy powder, C103, a critical metal powder used in hypersonics weaponry.
  • On December 19, the company provided an update to investors on its progress to date this month with several milestones tracking ahead of schedule. 

Recce Pharmaceuticals – Landmark commitment helps fund R&D costs

By Edison Investment Research

Recce recently reported that the Australian government has committed to providing up to A$55m in future cash rebates to reimburse upcoming R&D expenditure directed towards the company’s proprietary synthetic anti-infective programmes to June 2025. Notably, this binding agreement with the Australian government’s Department of Industry, Science and Resources (AusIndustry) extends the rebate programme that customarily reimburses 43.5% of eligible R&D expenditures incurred within Australia, to cover the anti-infective R&D activities Recce undertakes anywhere in the world. We view this as key given our expectation that US and global clinical trials will be needed to maximise the commercial potential of Recce’s products, notably lead candidate RECCE® 327 (R327). While our model already assumed the Australian government would reimburse 43.5% of Recce’s overseas R&D costs, there was a minor degree of uncertainty on whether this would be the case. Hence, the signing of this binding commitment with AusIndustry helps de-risk future funding needs for Recce as it advances its anti-infective programmes, notably R327 in sepsis/urosepsis and in complicated urinary tract infection (UTIs).


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: LG Display, Viva Republica and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Arb Trading with Stock Rights in Korea: A Basic Guide Featuring LG Display Offering
  • Key Beneficiaries of a Potential Viva Republica IPO in 2024


Arb Trading with Stock Rights in Korea: A Basic Guide Featuring LG Display Offering

By Sanghyun Park

  • Unlike typical Korean stock rights arbitrage, LG Display’s significant equity offering and active stock futures trading anticipate a spread opening, akin to the recent Hanwha Ocean scenario.
  • In contrast to Hanwha Ocean, the absence of major sellers, like KDB, sets this event apart. LG Electronics, the major shareholder with a 37.9% stake, intends to participate.
  • Despite differences from Hanwha Ocean, LG Display’s high retail shareholder presence implies a substantial likelihood of stock rights overhang, even without players like KDB.

Key Beneficiaries of a Potential Viva Republica IPO in 2024

By Douglas Kim

  • It was reported in numerous local media that Viva Republica has sent several RFPs to several large domestic securities companies to be underwriters of a potential IPO in 2024. 
  • Viva Republica is one of the largest Korean fintech companies. Market value of Viva Republica is estimated at more than 9 trillion won.
  • E World, Hanwha Securities, Hana Financial, and Korea Electronic Certification Co are major public companies that should benefit from the listing of Viva Republica. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Embassy Office Parks REIT Block – Likely Well Flagged and Overhang Will Be Removed and more

By | Daily Briefs, ECM

In today’s briefing:

  • Embassy Office Parks REIT Block – Likely Well Flagged and Overhang Will Be Removed
  • Inox India IPO Trading – Hot Demand for Cryogenics


Embassy Office Parks REIT Block – Likely Well Flagged and Overhang Will Be Removed

By Ethan Aw

  • Blackstone (BX US) is looking to raise around US$834m through a secondary block deal. This will be a clean-up as Blackstone fully exits from Embassy Office Parks REIT (EMBASSY IN).  
  • The deal is a large one to digest, at approximately 397.2 days of three month ADV and 20.7% of current mcap.  
  • In this note, we will talk about the selldown and run the deal through our ECM framework.

Inox India IPO Trading – Hot Demand for Cryogenics

By Ethan Aw

  • INOX India Limited (INOX IN) raised around US$175m in its Indian IPO, after pricing the deal at INR660/share. It will begin trading tomorrow on 21st Dec 2023.
  • Inox India is a manufacturer of cryogenic equipment. As per CRISIL, the firm was the largest Indian exporter of cryogenic tanks in terms of FY23 sales.
  • We have looked at various aspects of the deal in our previous notes. In this note, we talk about demand and trading dynamics.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Singapore: Singapore Airlines and more

By | Daily Briefs, Singapore

In today’s briefing:

  • Singapore Airlines (SIA SP | BUY | SGD: 8.07): Nov’ 2023 Op Stats, More Reason to Be Bullish


Singapore Airlines (SIA SP | BUY | SGD: 8.07): Nov’ 2023 Op Stats, More Reason to Be Bullish

By Mohshin Aziz

  • Singapore Airlines (SIA SP) (SIA) November operating statistics were good, passenger load factor rose by 1.9ppt YoY to 87.8%, and cargo load factor rose by a similar quantum  
  • Market observations suggest yields should remain at high levels and cost items such as fuel and USD-denominated items on a favorable downtrend 
  • If this performance continues, SIA will beat consensus easily. We recommend BUY with a TP of SGD8.07 – pegged to 10x FY24 PE. (+26% UPSIDE)  

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Thematic (Sector/Industry): Ohayo Japan | Market Retreat Intensifies; Panasonic Plays the States and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • Ohayo Japan | Market Retreat Intensifies; Panasonic Plays the States
  • 2024 High Conviction: Low Semiconductor Growth
  • 2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
  • 112: More Thoughts On Banks’ HTM Portfolio; Boston Fed Paper
  • GEM Banks; 2024 Conviction Calls
  • Why Subsystems Now


Ohayo Japan | Market Retreat Intensifies; Panasonic Plays the States

By Mark Chadwick

  • Overseas: SPX -1.5%; Stocks tumbled as investors locked in profits, ending the Dow and Nasdaq’s nine-day gains. FedEx’s disappointing outlook contributed to the index’s worst day since September.
  • Today: NKY Futs -1.9% v cash. JPY143; Yamaha Motors faces slowdown in US; Toyota recall; Chugoku to sell excess Uranium
  • Japan: Panasonic walked away from Oklahoma’s $698M battery offer, sparking concerns over megaproject subsidies and corporate gamesmanship.

2024 High Conviction: Low Semiconductor Growth

By Jim Handy

  • Objective Analysis has released its 2024 semiconductor forecast, calling for growth of below 5%
  • Other forecasters currently call for 11% to 17% growth, which would require another super cycle to accomplish
  • We do not see any event that will drive a 2024 super cycle, even with the current rapid adoption of AI in the data center

2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe

By Tina Banerjee

  • Despite ongoing recovery and fading effect of the COVID-19, 2023 was not a smooth sailing for the healthcare companies. All the countries and sub-sectors did not perform equally.
  • As we are heading into 2024, let us look back on the performance of some of our global healthcare stocks recommended throughout 2023.
  • LianBio (LIAN US) remained the best performer with 93% return in nearly eight months. Global Health (Medanta) (MEDANTA IN), top pick for March 2023, generated 79% return in nine months.     

112: More Thoughts On Banks’ HTM Portfolio; Boston Fed Paper

By Watchlist Investing

  • The Boston Federal Reserve put out a short white paper on the Silicon Valley Bank crash and the accounting for debt securities known as held-to-maturity or HTM.
  • It’s a nice short read and got me thinking about this issue again, which I examined back in May in Issue #100 (link below).
  • The question, which has not definitively resolved itself in academia or policy circles, centers around bank accounting and whether banks should be allowed to value bonds they’re not planning on selling (hence the term held-to-maturity) based on amortized cost.

GEM Banks; 2024 Conviction Calls

By Victor Galliano

  • Among bigger cap GEM banks, we pick four longs and one short as our conviction calls for 2024
  • Our core buys are Bank Mandiri from Indonesia, KB Financial from South Korea, China Merchants Bank and Banco do Brasil
  • Our key sell is Kotak Mahindra Bank from India which is richly valued, exposed to low prospective earnings growth and has low credit quality coverage

Why Subsystems Now

By Douglas O’Laughlin


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Credit: Vedanta Resources – Event Flash – Liability Management Exercise – Lucror Analytics and more

By | Credit, Daily Briefs

In today’s briefing:

  • Vedanta Resources – Event Flash – Liability Management Exercise – Lucror Analytics
  • Morning Views Asia: China South City


Vedanta Resources – Event Flash – Liability Management Exercise – Lucror Analytics

By Trung Nguyen

Vedanta Resources (VRL) has launched a consent solicitation for an extensive liability management exercise. The company is seeking consent from noteholders of its four bonds to extend the maturities of three of the bonds (the January 2024, August 2024 and 2025 notes) to 2027-2028. There will be no haircut on the principal, and the coupon for the August 2024 notes and 2025 notes will be increased to match that of the January 2024 notes.

In our opinion, the terms of the proposal are mixed and the timeline is very tight. Failure to receive the requisite consent may lead to the company defaulting on the January 2024 notes. The new financing cannot be used to repay the January 2024 notes if the liability management exercise does not go through. In this case, there would be no time for VRL to come up with a revised proposal before the maturity of the January 2024 notes.

We acknowledge the company’s efforts in terms of the improved security packages and higher coupons. We recommend that noteholders accept the proposal and provide consent.


Morning Views Asia: China South City

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief United States: Livent, United States Steel, Micron Technology, Pfizer Inc, Steelcase Inc Cl A, MillerKnoll and more

By | Daily Briefs, United States

In today’s briefing:

  • Allkem+Livent=Arcadium : Expected Index Flows
  • Nippon Steel/United States Steel Corp: Knock-Out Offer
  • The First Semi Micron to Guide 1Q24; Conservative Now but Likely Raise Later
  • Pfizer Inc (PFE US) – Continue to Lose Its Way in the Post-Pandemic Era
  • Steelcase, Inc. – Tweaking Estimates: Margins Improve, Sales Moderate
  • Steelcase, Inc. – 3QFY24 Earnings: Margins Drive EPS Upside
  • MillerKnoll, Inc. – 2QFY24 Earnings After Close


Allkem+Livent=Arcadium : Expected Index Flows

By Travis Lundy

  • Yesterday during the day, Allkem Ltd (AKE AU) shareholders approved the Scheme and Livent (LTHM US) shareholders approved the merger. The deal is done. Allkem last trades 21 Dec.
  • NEWCO starts trading 4 January in the US but the Arcadium Lithium CDIs start trading 22 Dec in Australia. S&P/ASX announced they will replace Allkem in the ASX200.
  • But I have been asked for a breakdown of flows and timing again, so I have put it into a handy table which I hope makes it less confusing.

Nippon Steel/United States Steel Corp: Knock-Out Offer

By Jesus Rodriguez Aguilar

  • Nippon Steel Corporation (5401 JP) and United States Steel (X US) have agreed an all-cash $55.00/share offer, 142% premium to where X traded before Cliff’s approach, a very generous 7x EV/24e EBITDA.
  • A determined buyer seeks market share in the lucrative US market, with no meaningful synergies expected and willingness to keep all US Steel jobs and (greener) growth projects.
  • Although unions and some lawmakers are voicing concerns, CFIUS shouldn’t pose a big hurdle. Spread is 12.04%/17.93% (gross/annualised, assuming late settlement by end of Q3 2024). Long.

The First Semi Micron to Guide 1Q24; Conservative Now but Likely Raise Later

By Andrew Lu

  • Driven by stronger PC/networking DRAM sales, Micron reports 5% stronger 4Q23 sales, 10-13ppts q/q margin improvement and 34% y/y decline in MOI to 5.2 months;
  • Micron guides 1Q24 sales growth 8-16% q/q and 38-49% y/y and gross margin of 12%, beating Bloomberg consensus estimates by 6ppts;
  • Rooms to raise: 1. 1Q24 sales of 18% q/q likely; 2. Turning profits sooner than expected; 3. +Free cash flow in 2024; 4. HBM3E for GH200/H200 to improve mix, margin. 

Pfizer Inc (PFE US) – Continue to Lose Its Way in the Post-Pandemic Era

By Xinyao (Criss) Wang

  • Pfizer seems to be the worst-performing large pharma stock of 2023 after it lowered 2024 forecast. The Company continues to grapple with plummeting demand for its COVID products
  • The acquisition of Seagen can’t turn things around. Except a few products that are still able to maintain growth, sales of vast majority products that we’re familiar with are declining. 
  • The growth engine of Pfizer in post-pandemic era is still uncertain. Even though Pfizer’s share price has fallen sharply, this may still not be the time for bottom fishing.

Steelcase, Inc. – Tweaking Estimates: Margins Improve, Sales Moderate

By Water Tower Research

  • This note revises our estimates for Steelcase following its 3QFY24 earnings call.
  • In short, for 4QFY24, we up our margin assumption, moderate our revenue assumption slightly, and shave our adjusted EPS estimate by $0.01.
  • Steelcase reported strong margins and steady orders in the 3QFY24 on Tuesday evening.

Steelcase, Inc. – 3QFY24 Earnings: Margins Drive EPS Upside

By Water Tower Research

  • After Tuesday’s close, Steelcase reported 3QFY24 adjusted EPS of $0.30, ahead of our $0.25 estimate and consensus of $0.23.
  • Revenue came in lighter than expected at $778 million versus our $804 million estimate and consensus of $796 million.
  • Steelcase delivered another quarter of gross margin improvement at 32.4%, up 370 bps versus 3QFY23, and 46 bps above our estimate. 

MillerKnoll, Inc. – 2QFY24 Earnings After Close

By Water Tower Research

  • MillerKnoll reports 2QFY24 earnings after market close on Wednesday, December 20, and will host its management conference call at 5:00 pm ET.
  • WTR is modeling EPS of $0.55, the midpoint of guidance, on revenue of $987 million. Consensus is $0.54, with an estimate range of $0.52-0.56.
  • Order trends. We are modeling orders in the Americas at +13.9% versus a poor year-ago quarter of -17.3%.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Event-Driven: Allkem+Livent=Arcadium : Expected Index Flows and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • Allkem+Livent=Arcadium : Expected Index Flows
  • Arb Trading with Stock Rights in Korea: A Basic Guide Featuring LG Display Offering
  • Toyo Construction (1890) – Everyone Hits Pause
  • Japan Bumpitrage Potential: T&K Toka, IJTT, Taisho, Shidax, Benesse, Tokyo Rakutenchi
  • Nippon Steel/United States Steel Corp: Knock-Out Offer
  • Whispir (WSP AU): Soprano & Pendula Jostle for Control
  • STAR50 Index Rebalance Preview: Four High Impact Changes in March
  • Quiddity Leaderboard ASX Mar 24: Allkem, Newmont, Costa, and Many More


Allkem+Livent=Arcadium : Expected Index Flows

By Travis Lundy

  • Yesterday during the day, Allkem Ltd (AKE AU) shareholders approved the Scheme and Livent (LTHM US) shareholders approved the merger. The deal is done. Allkem last trades 21 Dec.
  • NEWCO starts trading 4 January in the US but the Arcadium Lithium CDIs start trading 22 Dec in Australia. S&P/ASX announced they will replace Allkem in the ASX200.
  • But I have been asked for a breakdown of flows and timing again, so I have put it into a handy table which I hope makes it less confusing.

Arb Trading with Stock Rights in Korea: A Basic Guide Featuring LG Display Offering

By Sanghyun Park

  • Unlike typical Korean stock rights arbitrage, LG Display’s significant equity offering and active stock futures trading anticipate a spread opening, akin to the recent Hanwha Ocean scenario.
  • In contrast to Hanwha Ocean, the absence of major sellers, like KDB, sets this event apart. LG Electronics, the major shareholder with a 37.9% stake, intends to participate.
  • Despite differences from Hanwha Ocean, LG Display’s high retail shareholder presence implies a substantial likelihood of stock rights overhang, even without players like KDB.

Toyo Construction (1890) – Everyone Hits Pause

By Travis Lundy

  • In September, YFO (Yamauchi Family Office) upped its Tender Offer proposal to ¥1,255/share. YFO presented. The Toyo Special Committee met, interviewed, examined, deliberated, then last week rejected YFO’s proposal. 
  • The rejection was a three-parter. First, they rejected YFO for not bringing management/ownership experience. Second, they said the proposal didn’t add enough value. Third, the price was too low.
  • There were no metrics against which to measure anything. And now Toyo has apparently decided to withdraw its Tender Offer Proposal.

Japan Bumpitrage Potential: T&K Toka, IJTT, Taisho, Shidax, Benesse, Tokyo Rakutenchi

By Arun George

  • Japan’s merger arb is facing an unusual situation: six merger arb situations (>US$100 million market cap) where the shares have consistently traded through terms.
  • We evaluate the bumpitrage potential of these six Japanese merger arb situations on qualitative and quantitative metrics.
  • Based on our analysis, the ranking as measured by the highest bumpitrage potential in descending order are T&K Toka, IJTT, Taisho, Shidax, Benesse and Tokyo Rakutenchi.

Nippon Steel/United States Steel Corp: Knock-Out Offer

By Jesus Rodriguez Aguilar

  • Nippon Steel Corporation (5401 JP) and United States Steel (X US) have agreed an all-cash $55.00/share offer, 142% premium to where X traded before Cliff’s approach, a very generous 7x EV/24e EBITDA.
  • A determined buyer seeks market share in the lucrative US market, with no meaningful synergies expected and willingness to keep all US Steel jobs and (greener) growth projects.
  • Although unions and some lawmakers are voicing concerns, CFIUS shouldn’t pose a big hurdle. Spread is 12.04%/17.93% (gross/annualised, assuming late settlement by end of Q3 2024). Long.

Whispir (WSP AU): Soprano & Pendula Jostle for Control

By David Blennerhassett

  • On the 6 November, cloud communication outfit Whispir (WSP AU)  announced a A$0.46/share unconditional Offer, in cash, from mobile messaging software play Soprano Design.
  • The Offer price was a 92% premium to Whispir’s recent private placement, and a 60% premium to the undisturbed price. Whispir rejected the Offer.
  • Pendula subsequently emerged with a A$0.57/share NBIO. Soprano “countered” with A$0.52/share. Pendula upped its indicative Offer to A$0.60/share. An independent expert’s fair value is between A$0.486/share-A$0.565/share.

STAR50 Index Rebalance Preview: Four High Impact Changes in March

By Brian Freitas

  • The review period for the March rebalance ends 31 January. We expect the changes to be announced 23 February with the implementation taking place after the close on 8 March.
  • We expect the index committee to continue using a 6-month minimum listing history resulting in four changes to the index.
  • One way turnover is estimated at 3.3% resulting in a one-way trade of CNY 4,717m. The impact on the deletions will be much larger than that on the inclusions.

Quiddity Leaderboard ASX Mar 24: Allkem, Newmont, Costa, and Many More

By Janaghan Jeyakumar, CFA

  • In this insight, we take a look at the potential index changes for ASX 300, 200, 100, 50, and 20 in the run-up to the March 2024 index review.
  • I expect one change for ASX 20, one change for ASX 100, and four changes for ASX 200 during the March 2024 index rebal event.
  • Separately, there could also be one intra-review change for ASX 200 in February 2024.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Equity Bottom-Up: All That Glitters Is Not Gold: Forensic Analysis of Motisons and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • All That Glitters Is Not Gold: Forensic Analysis of Motisons
  • [Blue Lotus Sector Update]: Latest Developments in Short Video Point to Possibilities
  • [Meituan (3690 HK, BUY, TP HK$118) Company Update]: Why ByteDance’s Purchase of Eleme Is a Bad Idea?
  • Singapore Airlines (SIA SP | BUY | SGD: 8.07): Nov’ 2023 Op Stats, More Reason to Be Bullish
  • The First Semi Micron to Guide 1Q24; Conservative Now but Likely Raise Later
  • Philippines Exchange (PSE PM): Updates from Q3/Q4, Catalysts Lining Up for Long-Term
  • Full Report – Lifull (2120 JP)
  • Pfizer Inc (PFE US) – Continue to Lose Its Way in the Post-Pandemic Era
  • Pan American Silver – Skarn PEA confirms its early potential
  • MillerKnoll, Inc. – 2QFY24 Earnings After Close


All That Glitters Is Not Gold: Forensic Analysis of Motisons

By Nimish Maheshwari

  • Regulatory Tangles:Promoters faced cricket betting allegations, SEBI penalties, debarment from financial markets and a litany of investigations. Legal and financial risks loom due to regulatory delays and unresolved litigations.
  • Operational and Financial Hurdles:Excessive inventory, delayed payments, and opaque related-party transactions.Weaker margins, ROE, and underutilized manufacturing hint at broader governance frailty.
  • Debt Dilemmas and Transparency Concerns: Heavy reliance on high-interest promoter loans. Governance lapses are reflected in financial metrics, raising questions about transparency and conflicts of interest.

[Blue Lotus Sector Update]: Latest Developments in Short Video Point to Possibilities

By Ying Pan

  • We view both Weixin Video Account (WVA) and Douyin China as secondary assets to their respective parents, which in our view, may lead to them forming…(TBC)
  • However, rising competition in the short-play (短剧) market may put the two businesses in more direct confrontation, which may delay or diminish the chance for two to work together;
  • We view Tencent as the likely winner in the continuing evolution of short video as it considers various options to maximize the value of WVA traffic.

[Meituan (3690 HK, BUY, TP HK$118) Company Update]: Why ByteDance’s Purchase of Eleme Is a Bad Idea?

By Ying Pan

  • Local news reported an unnamed expert suggesting ByteDance might be buying Eleme for US$7bn, leading to share of Meituan to fall;
  • While we believe (1) buying a food delivery business to complement Douyin’s in-store business makes some sense and…
  • (2) ByteDance has been aggressive in pushing the boundary of its businesses, an entry into domestic food delivery is a daunting challenge that yields very little benefits for ByteDance;

Singapore Airlines (SIA SP | BUY | SGD: 8.07): Nov’ 2023 Op Stats, More Reason to Be Bullish

By Mohshin Aziz

  • Singapore Airlines (SIA SP) (SIA) November operating statistics were good, passenger load factor rose by 1.9ppt YoY to 87.8%, and cargo load factor rose by a similar quantum  
  • Market observations suggest yields should remain at high levels and cost items such as fuel and USD-denominated items on a favorable downtrend 
  • If this performance continues, SIA will beat consensus easily. We recommend BUY with a TP of SGD8.07 – pegged to 10x FY24 PE. (+26% UPSIDE)  

The First Semi Micron to Guide 1Q24; Conservative Now but Likely Raise Later

By Andrew Lu

  • Driven by stronger PC/networking DRAM sales, Micron reports 5% stronger 4Q23 sales, 10-13ppts q/q margin improvement and 34% y/y decline in MOI to 5.2 months;
  • Micron guides 1Q24 sales growth 8-16% q/q and 38-49% y/y and gross margin of 12%, beating Bloomberg consensus estimates by 6ppts;
  • Rooms to raise: 1. 1Q24 sales of 18% q/q likely; 2. Turning profits sooner than expected; 3. +Free cash flow in 2024; 4. HBM3E for GH200/H200 to improve mix, margin. 

Philippines Exchange (PSE PM): Updates from Q3/Q4, Catalysts Lining Up for Long-Term

By Sameer Taneja

  • Q3 2023 results for the Philippine Stock Exchange / (PSE PM) were uneventful. EBITDA margins were rock solid at>60%, and net margins were>40%. Revenues and profits were up 1.3%/51% YoY.
  • Cash and Investments at 4.8 bn pesos account for 32% of the market capitalization. The cash will aid in acquiring the remaining 79% stake in PDS.
  • Trading at 19x/17x FY23e/24e and a dividend yield of 5.3%/5.9%, there are several catalysts to drive earnings over the next few years (and investors are paid to wait). 

Full Report – Lifull (2120 JP)

By Sessa Investment Research

  • LIFULL runs the LIFULL Home’s real estate website. Compared to its main rival, whose strategy is focused mainly on the quantity of listings, LIFULL’s aim is to achieve greater quality, as measured by the percentage of inquiries that lead to sales for professional real estate clients.
  • While others primarily charge a fixed fee for listings, LIFULL charges a combination of fixed fees and incentive fees based on the number of inquiries received for a listing.
  • Compared to its main rival LIFULL tends to invest more heavily in software development and considerably less on advertising. 

Pfizer Inc (PFE US) – Continue to Lose Its Way in the Post-Pandemic Era

By Xinyao (Criss) Wang

  • Pfizer seems to be the worst-performing large pharma stock of 2023 after it lowered 2024 forecast. The Company continues to grapple with plummeting demand for its COVID products
  • The acquisition of Seagen can’t turn things around. Except a few products that are still able to maintain growth, sales of vast majority products that we’re familiar with are declining. 
  • The growth engine of Pfizer in post-pandemic era is still uncertain. Even though Pfizer’s share price has fallen sharply, this may still not be the time for bottom fishing.

Pan American Silver – Skarn PEA confirms its early potential

By Edison Investment Research

Pan American Silver (PAAS) released a preliminary economic assessment (PEA) of the La Colorada Skarn project, confirming its potential to become a large-scale operation producing an average 17.2Moz of silver per annum over the first 10 years of its 17-year mine life. At a base case throughput rate of 50ktpd, the company estimates the project’s post-tax NPV8 at US$1.1bn, with an IRR of 14% and a payback period of 4.3 years. We intend to update our valuation shortly to incorporate the PEA and the prevailing stronger than expected gold and silver prices.


MillerKnoll, Inc. – 2QFY24 Earnings After Close

By Water Tower Research

  • MillerKnoll reports 2QFY24 earnings after market close on Wednesday, December 20, and will host its management conference call at 5:00 pm ET.
  • WTR is modeling EPS of $0.55, the midpoint of guidance, on revenue of $987 million. Consensus is $0.54, with an estimate range of $0.52-0.56.
  • Order trends. We are modeling orders in the Americas at +13.9% versus a poor year-ago quarter of -17.3%.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: Nexchip Semiconductor , Tencent, Meituan, China South City, Vipshop Holdings and more

By | China, Daily Briefs

In today’s briefing:

  • STAR50 Index Rebalance Preview: Four High Impact Changes in March
  • [Blue Lotus Sector Update]: Latest Developments in Short Video Point to Possibilities
  • [Meituan (3690 HK, BUY, TP HK$118) Company Update]: Why ByteDance’s Purchase of Eleme Is a Bad Idea?
  • Morning Views Asia: China South City
  • [Vipshop (VIPS US, BUY, TP US$18.1) TP Change]: Discount Offerings Remain Hot Given Cold Consumption


STAR50 Index Rebalance Preview: Four High Impact Changes in March

By Brian Freitas

  • The review period for the March rebalance ends 31 January. We expect the changes to be announced 23 February with the implementation taking place after the close on 8 March.
  • We expect the index committee to continue using a 6-month minimum listing history resulting in four changes to the index.
  • One way turnover is estimated at 3.3% resulting in a one-way trade of CNY 4,717m. The impact on the deletions will be much larger than that on the inclusions.

[Blue Lotus Sector Update]: Latest Developments in Short Video Point to Possibilities

By Ying Pan

  • We view both Weixin Video Account (WVA) and Douyin China as secondary assets to their respective parents, which in our view, may lead to them forming…(TBC)
  • However, rising competition in the short-play (短剧) market may put the two businesses in more direct confrontation, which may delay or diminish the chance for two to work together;
  • We view Tencent as the likely winner in the continuing evolution of short video as it considers various options to maximize the value of WVA traffic.

[Meituan (3690 HK, BUY, TP HK$118) Company Update]: Why ByteDance’s Purchase of Eleme Is a Bad Idea?

By Ying Pan

  • Local news reported an unnamed expert suggesting ByteDance might be buying Eleme for US$7bn, leading to share of Meituan to fall;
  • While we believe (1) buying a food delivery business to complement Douyin’s in-store business makes some sense and…
  • (2) ByteDance has been aggressive in pushing the boundary of its businesses, an entry into domestic food delivery is a daunting challenge that yields very little benefits for ByteDance;

Morning Views Asia: China South City

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


[Vipshop (VIPS US, BUY, TP US$18.1) TP Change]: Discount Offerings Remain Hot Given Cold Consumption

By Ying Pan

  • Amid demand by consumers for cost effective items, we expect that demand for discounted apparel will sustain into 2024…
  • We expect high levels of apparel sales continued in December, as VIPS reported double-digit GMV growth for various types of winter related apparel items during 12/12…
  • China’s cost-conscious spending environment favors VIPS, in our view. We maintain BUY and raise TP to US$ 18.1, implying 7x FY24 non-GAAP P/E.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars